The landscape of biomarkers for the management of Alzheimer’s disease

Giovanni Frisoni

At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Giovanni Frisoni, MD, from Geneva University Hospital, Geneva, Switzerland, discusses the current clinical use of biomarkers in Alzheimer’s disease as well as the development of biomarkers for early diagnosis, particularly in asymptomatic individuals that will lead to the application of personalized therapies.

Share this video  
Similar topics
Related videos
2:08
What has been learnt from Aβ vaccine research?
Johannes Attems
1:41
Understanding the relationship between MAPT mutations and disease pathology
Celeste Karch
10:19
Clinical trial for BAN2401 in early Alzheimer’s: combining ADCOMS and Bayesian statistics
Lynn Kramer
4:56
Two sides to the story: clearance in Alzheimer’s disease
Zhen Zhao
4:54
Two exciting projects that could change the future of Alzheimer's disease
Cynthia Lemere
Alzheimer’s Disease
EAN 2016
Interview
29th May 2016
More from Giovanni Frisoni
Task force from Geneva: Roadmap for biomarker validation in Alzheimer’s disease
Ethical considerations of biomarker use in prodromal Alzheimer’s disease
The content of VJDementia is intended for healthcare professionals